{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Kim C"],"pubmed_abstract":["18F-GP1 is a derivative of elarofiban with a high affinity to activated platelet glycoprotein IIb/IIIa (GPIIb/IIIa) and favorable in vivo characteristics for thrombus imaging in preclinical models. We aimed to explore the detection rate of thromboembolic foci with 18F-GP1 positron emission tomography/computed tomography (PET/CT) in patients with acute venous thromboembolism (VTE), and to evaluate the safety, biodistribution, pharmacokinetics, and metabolism of 18F-GP1. Methods: We studied patients who had signs or symptoms of acute deep vein thrombosis (DVT) of the leg or acute pulmonary embolism (PE) within 14 days prior to 18F-GP1 PET/CT, and had thromboembolic foci confirmed by conventional imaging (n = 10 for DVT and n = 10 for PE). Dynamic whole-body PET/CT images were acquired for up"],"journal":["Journal of nuclear medicine : official publication, Society of Nuclear Medicine"],"pagination":["jnumed.118.212084"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8833852"],"repository":["biostudies-literature"],"pubmed_title":["Glycoprotein IIb/IIIa receptor imaging with 18F-GP1 positron emission tomography for acute venous thromboembolism: an open-label, non-randomized, first-in-human phase 1 study."],"pmcid":["PMC8833852"],"pubmed_authors":["Kim C","Son HJ","Chae SY","Kim B","Lee SJ","Jin S","Han Y","Kwon TW","Cho YP","Koglin N","Lee JS","Jang S","Berndt M","Lee DH","Oh SJ","Sung C","Oh JS","Moon DH","Stephens AW"],"additional_accession":[]},"is_claimable":false,"name":"Glycoprotein IIb/IIIa receptor imaging with 18F-GP1 positron emission tomography for acute venous thromboembolism: an open-label, non-randomized, first-in-human phase 1 study.","description":"18F-GP1 is a derivative of elarofiban with a high affinity to activated platelet glycoprotein IIb/IIIa (GPIIb/IIIa) and favorable in vivo characteristics for thrombus imaging in preclinical models. We aimed to explore the detection rate of thromboembolic foci with 18F-GP1 positron emission tomography/computed tomography (PET/CT) in patients with acute venous thromboembolism (VTE), and to evaluate the safety, biodistribution, pharmacokinetics, and metabolism of 18F-GP1. Methods: We studied patients who had signs or symptoms of acute deep vein thrombosis (DVT) of the leg or acute pulmonary embolism (PE) within 14 days prior to 18F-GP1 PET/CT, and had thromboembolic foci confirmed by conventional imaging (n = 10 for DVT and n = 10 for PE). Dynamic whole-body PET/CT images were acquired for up","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2025-06-01T00:52:08.948Z","creation":"2024-11-13T10:45:03.903Z"},"accession":"S-EPMC8833852","cross_references":{"pubmed":["29959214"],"doi":["10.2967/jnumed.118.212084"]}}